Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 18/20 | 0.43 |
| ▸ | ITGAV | P06756 | 18/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 7/20 | 0.43 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.43 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.43 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6804895 | 0.90 | ITGB3 (0.49) | MDM4MDM2ITGB3ITGAVITGB1 | |
| SCHEMBL6806429 | 0.90 | ITGB3 (0.42) | MDM4MDM2ITGB3ITGAVITGB1 | |
| SCHEMBL7018419 | 0.90 | ITGB3 (0.42) | MDM4MDM2ITGB3ITGAVITGB1 | |
| SCHEMBL6809475 | 0.89 | ITGB3 (0.49) | MDM4MDM2ITGB3ITGAVITGB1 | |
| SCHEMBL6799591 | 0.89 | ITGB3 (0.44) | MDM4MDM2ITGB3ITGAVITGB1 | |
| SCHEMBL6809449 | 0.85 | ITGB3 (0.44) | MDM4MDM2ITGB3ITGAVITGB1 | |
| Trifluoroacetic Acid SCHEMBL6802228 | 0.80 | ITGB3 (0.48) | MDM4MDM2ITGB3ITGAVITGB1 | |
| Trifluoroacetic Acid SCHEMBL6806426 | 0.80 | ITGB3 (0.48) | MDM4MDM2ITGB3ITGAVITGB1 | |
| SCHEMBL6802895 | 0.79 | ITGB3 (0.40) | MDM4MDM2ITGB3ITGAVITGB1 | |
| SCHEMBL6804811 | 0.79 | ITGB3 (0.48) | MDM4MDM2ITGB3ITGAVITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043994-A1 | Gem-substituted alpha v beta 3 antagonists | PHARMACIA CORPORATION | 2004-03-04 | — | — | US | disclosed |
| EP-1313705-A1 | GEM-SUBSTITUTED ALPHA V BETA 3 INTEGRIN ANTAGONISTS | Pharmacia Corporation (US) | 2003-05-28 | — | — | EP | disclosed |
| US-6531494-B1 | Gem-substituted αvβ3 antagonists | PHARMACIA CORPORATION | 2003-03-11 | — | — | US | disclosed |
| WO-2002018340-A1 | GEM-SUBSTITUTED α v β 3 INTEGRIN ANTAGONISTS | PHARMACIA CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043994-A1 | Gem-substituted alpha v beta 3 antagonists | CACNG5, ITGAV, ITGA5 | MDM4 4582/4885MDM2 4240/4885ITGB3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.